Industry executive with more than 25 years of finance and strategic leadership experienceBOSTON and SAN DIEGO, Jan. 08, 2025 (GLOBE…
Case reports published in medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunosuppressed…
Araris will use proprietary AraLinQ™ linker-conjugation platform to generate novel ADCs using antibodies against targets provided by ChugaiAraris to receive…
– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue…
All-Stock Acquisition Strategy Targets Multiple Small Companies with FDA-Approved Products to Drive Growth and Shareholder ValueWARRINGTON, Pa., Jan. 08, 2025…
Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated…
Appointment Further Strengthens Leadership Team; Follows Appointment of Volker Knappertz, M.D., as Executive Vice President of Research & DevelopmentBASEL, Switzerland,…
NORWOOD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced…
Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract…
VG901 is the first-in-class and only clinical-stage therapy designed to deliver the functional CNGA1 gene intravitreally (IVT) to target retinal…